Abstract
Background and Aim While considerable success has been achieved in the management of patients hospitalized with severe coronavirus disease 2019 (COVID-19), far less progress has been made with early outpatient treatment. We assessed whether the implementation of a home treatment algorithm – designed based upon on a pathophysiologic and pharmacologic rationale - during the initial, mild phase of COVID-19, could effectively reduce hospital admissions.
Methods This fully academic, matched-cohort study evaluated outcomes in 108 consecutive consenting patients with mild COVID-19 managed at home by their family doctors from January 2021 to May 2021, according to the proposed treatment algorithm and in 108 age-, sex-, and comorbidities-matched patients who were given other therapeutic schedules (ClinicalTrials.gov: NCT04854824). The primary outcome was COVID-19-related hospitalization. Analyses were by intention-to-treat.
Results One (0.9%) patient in the ‘recommended’ cohort and 12 (11.1%) in the ‘control’ cohort were admitted to hospital (P=0.0136). The proposed algorithm reduced, by 85%, the cumulative length of hospital stays (from 141 to 19 days) and related costs (from € 60.316 to € 9.058). Only 9.8 patients needed to be treated with the recommended algorithm to prevent one hospitalization event. The rate of resolution of major symptoms was numerically, but not significantly, higher in the ‘recommended’ compared to the ‘control’ cohort (97.2% versus 93.5%, respectively; P=0.322). Other symptoms lingered in a lower proportion of patients in the ‘recommended’ than in the‘control’ cohort (20.4% versus 63.9%, respectively; P<0.001), and for a shorter period.
Conclusion The adoption of the proposed outpatient treatment algorithm during the early, mild phase of COVID-19 reduced the incidence of subsequent hospitalization and related costs.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT04854824
Funding Statement
The study was partially supported by a generous donation from QuattroR SGR SpA to the Istituto di Ricerche Farmacologiche Mario Negri IRCCS. The QuattroR SGR SpA did not have any role in study design, in the collection, analysis and interpretation of data, in writing the report, or in the decision to submit the paper for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The COVER 2 study was approved by the Ethical Committee of Insubria (Varese, Italy; 27 July 2021) and registered at ClinicalTrials.gov (NCT04854824). In COVER 2, participants in the recommended algorithm cohort provided written informed consent to their family doctors at enrolment. Subjects in the control cohort (from the ORIGIN database) signed a consent form to participate in the ORIGIN study, which also explicitly included consent to use their data for future studies, such as COVER 2.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Sharing individual participant data with third parties was not specifically included in the informed consent form of the study, and unrestricted diffusion of such data may pose a potential threat of revealing the identities of participants, as permanent data anonymization was not carried out (patient records were instead de-identified per protocol during the data retention process). To minimize this risk, individual participant data that underlie the results reported in this article will be available after three months and for up to five years following article publication. The researchers shall submit a methodologically sound proposal to Dr. Annalisa Perna (annalisa.perna{at}marionegri.it), Head of the Laboratory of Biostatistics of the Department of Renal Medicine of the Istituto di Ricerche Farmacologiche Mario Negri IRCCS. To gain access, data requestors will need to sign a data access agreement and obtain the approval of the local ethics committee.
